ArticleRheumatology advances in practice2026
Metabolic syndrome and knee osteoarthritis: associations with disease stage and pain.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Metabolic Syndrome (MetS) is associated with OA progression and pain. However, its relationship with outcomes in early-stage disease remains unclear. We assessed associations of MetS with radiographic stage and knee pain in individuals with symptomatic knee OA. Methods: We analysed cross-sectional baseline data from 251 participants in the Western Ontario Registry for Early Osteoarthritis (WOREO) Knee Study. Associations between MetS and radiographic stage were assessed using modified Poisson regression. Associations with knee pain, measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS) pain scale, were evaluated using multiple linear regression accounting for within-participant correlation. Analyses were stratified by OA stage and adjusted for body mass index (BMI). Results: MetS was associated with a higher prevalence of late-stage knee OA [adjusted prevalence ratio 1.45 (95% CI 1.16, 1.81)]. After BMI adjustment, hypertension and haemoglobin A1c remained associated with late-stage disease. Participants with MetS reported worse knee pain, with lower KOOS pain scores [β = -14.70 (95% CI -20.92, -8.47)], particularly in early-stage disease [β = -14.15 (95% CI -20.37, -7.93)]. Dyslipidaemia (elevated triglycerides and reduced high-density lipoprotein cholesterol were also associated with worse pain in early-stage disease. Conclusion: MetS and its components are associated with greater radiographic severity and clinically meaningful worsening of pain, especially in early-stage knee OA, independent of BMI. These findings suggest that early identification and management of metabolic disease may represent a modifiable target to improve OA outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.